SARS: No evidence that any of the treatments workedSeptember 12, 2006The SARS virus set alarm bells ringing across the world when it first appeared in 2002, but now a review of the effectiveness of the treatments used against it has found no evidence that any of them worked. The review was commissioned by the World Health Organization and has been published in PLoS Medicine. Severe acute respiratory syndrome (SARS) is caused by a virus; the main symptoms are pneumonia and fever. The virus is passed on when people sneeze or cough. In 2003 there were over 8,000 cases and 774 deaths worldwide. The situation was alarming, because the first ever cases only appeared in 2002, in China, and so the best way to treat this new disease was unknown. Not many drugs are effective against viruses and all doctors can usually do with a viral disease is to treat symptoms like fever and inflammation, and rely on the body's own immune system to fight off the virus. However, in recent years a number of antiviral drugs have been developed (for example, there are several in use against HIV/AIDS) and there was hope that some of them might be active against SARS. Steroids have also been used in SARS treatment to try to reduce the inflammation of the lungs. To find out which, if any, of the potential treatments were effective, a number of research studies were carried out, both during and since the outbreak. The World Health Organization (WHO) established an International SARS Treatment Study Group, which recommended that a 'systematic review' of potential SARS treatments should be carried out. In particular, it was considered important to bring together all the available evidence on the use of certain antiviral drugs (ribavirin, lopinavir and ritonavir), steroids, and proteins called immunoglobulins which are found naturally in human blood. The WHO group wanted to know how these treatments affected the virus outside the body ('in vitro') and whether it helped the condition of patients and reduced the death rate, especially in those patients who developed a dangerous complication called acute respiratory distress syndrome. Researchers conducted a comprehensive search for information from research studies that fitted carefully pre-defined selection criteria. They found 54 SARS treatment studies, 15 in- vitro studies, and three acute respiratory distress syndrome studies. Some of the in-vitro studies with the antiviral drugs found that a particular drug reduced the reproduction rate of the viruses, but most of the studies of these drugs in patients were inconclusive. Of 29 studies on steroid use, 25 were inconclusive and four found that the treatment caused possible harm. From the published studies, it is not possible to say whether any of the treatments used against SARS were effective. It is now many months since any new cases have been reported, but it is possible that the same or a similar virus might cause outbreaks in the future. It is disappointing that none of the research on SARS so far is likely to be useful in helping to decide on the best treatments to use in such an outbreak. The authors examined the weaknesses of the studies they found and urge that more effective methods of research should be applied in any future outbreaks. Their recommendations mean that researchers should be better prepared to learn from potential future outbreaks. Public Library of Science |
|||||||||||||||||||||
| Related SARS Current Events and SARS News Articles 2-pronged protein attack could be source of SARS virulence Ever since the previously unknown SARS virus emerged from southern China in 2003, University of Texas Medical Branch at Galveston virologists have focused on finding the source of the pathogen's virulence - its ability to cause disease. Will genomics help prevent the next pandemic? This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease. Paradigm shift needed to combat drug resistance When people travel, bacteria and other infectious agents travel with them. As about a billion people cross international borders each year, many more billions of the bugs come along for the ride. What are coral reef services worth? $130,000 to $1.2 million per hectare, per year: experts Experts concluding the global DIVERSITAS biodiversity conference today in Cape Town described preliminary research revealing jaw-dropping dollar values of the "ecosystem services" of biomes like forests and coral reefs - including food, pollution treatment and climate regulation. Should noninvasive ventilation be considered a high-risk procedure during an epidemic? Contrary to current policies recommending that non-invasive ventilation be avoided during an infectious outbreak, the author of a commentary in CMAJ (Canadian Medical Association Journal) argues that it should be used expeditiously in this setting. World will miss 2010 target to stem biodiversity loss, experts say The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science. Surgical masks and N95 respirators provide similar protection against influenza A McMaster University study has found that surgical masks appear to be as good as N95 respirators in protecting health-care workers against influenza. Medical ethics experts identify, address key issues in H1N1 pandemic The anticipated onset of a second wave of the H1N1 influenza pandemic could present a host of thorny medical ethics issues best considered well in advance, according to the University of Toronto Joint Centre for Bioethics, which today released nine papers for public discussion. Swine Flu Could Wreak More Havoc on U.S. Economy, Says UAB Economist H1N1 influenza could slow growth in key industries and stall already-weak GDP growth in the third and fourth quarters of 2009, says a health economist in the University of Alabama at Birmingham (UAB) School of Business. Public attitudes to new technology: Lessons for regulators New technologies may change our lives for the better, but sometimes they have risks. Communicating those benefits and risks to the public, and developing regulations to deal with them, can be difficult - particularly if there's already public opposition to the technology. More SARS Current Events and SARS News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||